SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
203 hedge funds and large institutions have $994M invested in SANGAMO THERAPEUTICS INC in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 65 increasing their positions, 72 reducing their positions, and 39 closing their positions.
55% more call options, than puts
Call options by funds: $18.7M | Put options by funds: $12M
0.11% more ownership
Funds ownership: 55.35% → 55.46% (+0.11%)
10% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 72
9% less funds holding
Funds holding: 223 → 203 (-20)
19% less capital invested
Capital invested by funds: $1.22B → $994M (-$227M)
46% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 39
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$14.4M |
| 2 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$11.4M |
| 3 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
+$11.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.17M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$11.3M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
-$9.19M |
| 3 |
Goldman Sachs
New York
|
-$7.33M |
| 4 |
CC
Casdin Capital
New York
|
-$7.14M |
| 5 |
Renaissance Technologies
New York
|
-$6.91M |
SGMO Hedge Fund Activity: Q1 2021 in Review
203 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q1 2021, worth a combined $994M — down 19% from $1.22B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of SGMO and 21 opened new positions — a net loss of 18 holders — while 72 trimmed existing stakes and 65 added.
The largest buyer was JP Morgan Chase, adding an estimated $14.4M. The largest seller was UBS AM, cutting an estimated $11.3M.
- 203 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q1 2021, down from 223 in Q4 2020.
- Funds reported $994M of SANGAMO THERAPEUTICS INC stock for Q1 2021, down 19% quarter-over-quarter.
- 21 funds opened new SANGAMO THERAPEUTICS INC positions in Q1 2021 and 39 closed out, a net change of -18 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q1 2021 was JP Morgan Chase, an estimated $14.4M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q1 2021 was UBS AM, an estimated $11.3M sold.
Based on aggregated 13F filings for Q1 2021.